Which cancers have shown benefit from olaparib combinations?
Olaparib (a PARP inhibitor) has combination chemotherapy benefit primarily in cancers where tumors show DNA-damage repair defects or where PARP inhibition has clinical synergy with other cytotoxic regimens. The provided information does not list specific tumor types or trials, so the exact set of tumor types that benefit from olaparib combination chemotherapy can’t be determined from it.
Do olaparib combos work better in BRCA-mutant or HRD tumors?
PARP inhibitors like olaparib are generally most effective when tumors rely on PARP-mediated repair pathways, which is commonly the case in BRCA1/2-mutant and homologous recombination deficient (HRD) cancers. Combination strategies are often built around either increasing DNA damage or exploiting HRD-related vulnerability, but the specific tumor categories that benefit from olaparib chemotherapy combinations are not provided here.
Are the benefits limited to solid tumors, or do they include blood cancers?
Olaparib is used in certain malignancies across solid tumors; whether a given “combination chemotherapy” approach benefits blood cancers depends on the specific indication and study design. Without the provided dataset or references, the tumor types cannot be stated reliably.
What tumor types should you look for when searching “olaparib plus chemotherapy”?
When people search for “olaparib chemotherapy combos,” they’re usually looking for studies that include platinum-based chemotherapy and/or agents that induce DNA damage in tumors with HRD/BRCA features. But the specific tumor types (e.g., which organs/biomarker-defined subgroups) that have documented combination benefit are not included in the information you provided.
What information would let me answer precisely?
Share any of the following, and I can map the olaparib combination benefit to the tumor types accurately:
- the source text/table/trial list you’re using
- the specific combination regimen(s) (e.g., olaparib + paclitaxel, olaparib + carboplatin, etc.)
- the study name(s) or NCT numbers
- the biomarkers required in the trial (BRCA mutation, HRD score, etc.)
Sources
No sources were provided with your question, so I can’t cite evidence-based tumor types that benefit from olaparib chemotherapy combinations.